K-Ras-independent effects of the farnesyl transferase inhibitor L- 744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells

Neoplasia

Volumn 2, Issue 3, 2000, Pages 261-272

  Song, Si Young ^a   Meszoely, Ingrid M ^a   Coffey, Robert J ^a   Pietenpol, Jennifer A ^b   Leach, Steven D ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer; Cyclin B cdc2; Farnesylation; Mitosis; Pancreas

Indexed keywords

CYCLIN B1; DNA FRAGMENT; PROTEIN FARNESYLTRANSFERASE; PROTEIN KINASE;

ADENOCARCINOMA; ARTICLE; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; IONIZING RADIATION; ONCOGENE; PANCREAS DUCT; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, DUCTAL, BREAST; CYCLIN B; ENZYME INHIBITORS; G2 PHASE; GENES, RAS; HUMANS; METHIONINE; MITOSIS; PANCREATIC NEOPLASMS;

EID: 0011758687     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Zhang FL, and Casey PJ (1996). Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65, 241-269.
2. Gibbs JB, and Oliff A (1997). The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 37, 143-166.
3. Armstrong SA, Hannah VC, Goldstein JL, and Brown MS (1995). CAAX geranylgeranyl transferase transfers farnesyl as effeciently as geranylgeranyl to RhoB. J Biol Chem 270, 7864-7868.
4. James GL, Goldstein JL, and Brown MS (1995). Polylysine and CVIM. sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 270, 6221-6226.
5. Andres AD, Seabra MC, Brown MS, Armstrong SA, Smeland TE, Cremers FPM, and Goldstein JL (1993). cDNA cloning of component A of Rab geranylgeranyltransferase and demonstration of its role as a Rab escort protein. Cell 73, 1091-1099.
6. Barbacid M (1987). Ras genes. Annu Rev Biochem 56, 779-827.
7. Boguski MS, and McCormick F (1993). Proteins regulating ras and its relatives. Nature 366, 643-654.
8. Hruban RH, Van Mansfeld ADM, Offerhaus GJ, et al. (1993). K-ras oncogene activation in adenocarcinoma of the human pancreas. Am J Pathol 143, 545-554.
9. Almoguera C, Shibata D, Forrester K, et al. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549-554.
10. Schafer WR, Kim R, Sterne R, Thorner J, Kim S-H, et al. (1989). Genetic and pharmacologic suppression of oncogenic mutations in RAS genes of yeast and humans. Science 245, 379-385.
11. Stokoe D, Macdonald SG, Cadwallader K, Symons M, and Hancock JF (1994). Activation of Raf as a result of recruitment to the plasma membrane. Science 264, 1463-1467.
12. Gibbs JB, Oliff A, and Kohl NE (1994). Farnesyltransferase inhibitors: Ras research yields potential cancer therapeutic. Cell 77, 175-178.
13. Lobell RB, and Kohl NE (1998). Pre-clinical development of farnesyltransferase inhibitors. Cancer Metastasis Rev 17, 203-210.
14. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, and Rosen N (1995). A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55, 5302-5309.
15. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, and Gibbs JB (1993). Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260, 1934-1937.
16. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, and Marsters JC Jr (1993). Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260, 1937-1942.
17. Kohl NE, Wilson FR, Mosser SD, Giuliani E, DeSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee TJ, Smith RL, Grahm SL, Hartman GD, Gibbs JB, and Oliff A (1994). Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 91, 9141-9145.
18. Kohl NE, Omer CA, Conner MW, Davide JP, Anthony NJ, deSolms SJ, Guiliani EA, Gomez RP, Graham SL, Hamilton K, Handt LK, Hartman GD, Koblan KS, Krat AM, Miller PJ, Mosser SM, O'Neill TJ, Rands E, Schaber ME, Gibbs JB, and Oliff A (1995). Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1, 792-797.
19. Landis SH, Murray T, Bolden S, and Wingo PA (1998). Cancer statistics, 1998. CA-Cancer J Clin 48, 6-29.
20. Leach SD (1998). Resectable pancreatic adenocarcinoma: strategies to improve local tumor control. In Pancreatic Cancer Molecular and Clinical Management Prospects, F Sarkar and M Dugan (Eds). Eaton Publishing, Natick, MA, pp. 145-156.
21. Carter G, Gilbert C, and Lemoine NR (1995). Effects of antisense oligonucleotides targeting K-ras expression in pancreatic cancer cell lines. Int J Oncol 6, 1105-1112.
22. Shichinohe T, Senmaru N, Furuuchi K, et al. (1996). Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y. J Surg Res 66, 125-130.
23. Leach SD, Berger DH, Davidson BS, et al. (1998). Enhanced Krev-1 expression inhibits the growth of pancreatic adenocarcinoma cells. Pancreas 16, 491-498.
24. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, and Kern SE (1994). p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54, 3025-3033.
25. Caldas C, Hahn SA, da Costa LT, et al. (1994). Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8, 27-32.
26. Leach SD, Scatena CD, Keefer CJ, Goodman HA, Song SY, Yang L, and Pietenpol JA (1998). Negative regulation of Wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis. Cancer Res 58, 3231-3236.
27. Wat1/Cip1 inhibition of cyclin E/Cdk2 activity prevents endoreduplication after miotic spindle disruption. Mol Cell Biol 19, 205-215.
28. Sepp-Lorenzino L, and Rosen N (1998). A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J Biol Chem 273, 20243-20251.
29. Rhind N, Fumari B, and Russell P (1997). Cdc2 tyrosine phosphorylation is required for the DNA damage checkpoint in fission yeast. Genes Dev 11, 504-511.
30. O'Connell MJ, Raleigh JM, Verkade HM, and Nurse P (1997). Chk1 is a Wee1 kinase in the G2 DNA damage checkpoint inhibiting Cdc2 by Y15 phosphorylation. EMBO J 16, 545-554.
31. Cdc2 activation required for apoptosis. Science 263, 1143-1145.
32. Shimizu T, O'Connor PM, Kohn KW, and Pommier Y (1995). Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 55, 228-231.
33. Fotedar R, Flatt J, Gupta S, Margolis RL, Fitzgerald P, Messier H, and Fotedar A (1995). Activation-induced T-cell death is cell cycle dependent and regulated by cyclin B. Mol Cell Biol 15, 932-942.
34. Cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1β-converting enzyme-related proteases. Cancer Res 56, 4551-4555.
35. v12 proteins to farnesyltransferase inhibitors in rat1 cells. Proc Natl Acad Sci USA 93, 4454-4458.
36. Fiordalisi JJ, Rushton BC, Toussaint LG, Johnson RL, and Cox AD (1999). High affinity for Ftase and alternative prenylation contribute individually to K-ras resistance to FTIs. Proc Am Assoc Cancer Res 40, 521.
37. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin CC, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, and Bishop WR (1998). Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 58, 4947-4956.
38. Ura H, Obara T, Shudo R, Itoh A, Tanno S, Fujii T, Nishino N, and Kohgo Y (1998). Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts. Mol Carcinog 21, 93-99.
39. Sumi S, Beauchamp RD, Townsend CM Jr, Pour PM, Ishizuka J, and Thompson JC (1994). Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. Pancreas 9, 657-661.
40. Lebowitz PF, Sakamuro D, and Prendergast GC (1997). Farnesyl transferase inhibitors induce apoptosis of ras-transformed cells denied substratum attachment. Cancer Res 57, 708-713.
41. Barrington RE, Subler MA, Rands E, Omer CA, Miller PJ, Hundley JE, Koester SK, Troyer DA, Bearss DJ, Conner MW, Gibbs JB, Hamilton K, Koblan KS, Mosser SD, O'Neill TJ, Schaber MD, Senderak ET, Windle JJ, Oliff A, and Kohl NE (1998). A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 18, 85-92.
42. Norgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ Jr, Poulsen HS, and Moses HL (1999). Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res 5, 35-42.
43. Miquel K, Pradines A, Sun J, Qian Y, Hamilton AD, Sebti SM, and Favre G (1997). GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res 57, 1846-1850.
44. Stewart ZA, Mays D, and Pietenpol JA (1999). Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res 59, 3831-3837.
45. Suzuki N, Del Villar K, and Tamanoi F (1998). Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. Proc Natl Acad Sci USA 95, 10499-10504.
46. Ranganathan S, McCauley RA, and Hudes GR (1999). Combined cell cycle and cytotoxic effects of paclitaxel and R115777, a specific inhibitor of p21 ras function and protein farnesylation in human prostate and breast carcinoma cell lines. Proc Am Assoc Cancer Res 40, 523.
47. Moasser MM, Sep-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, and Rosen N (1998). Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 95, 1369-1374.
48. Terasima R, and Tolmach LJ (1963). X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 140, 490-492.
49. Sinclair WK, and Morton RA (1966). X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29, 450-457.
50. Gorodetsky R, Levdansky L, Ringel I, and Vexler A (1998). Paclitaxel-induced modification of the effects of radiation and alterations in the cell cycle in normal and tumor mammalian cells. Radiat Res 150, 283-291.
51. Tishler RB, Geard CR, Hall EJ, and Schiff PB (1992). Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52, 3495-3497.
52. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, and Pai JK (1997). K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272, 14459-14564.
53. Dalton MB, Fantle KS, Bechtold HA, DeMaio L, Evans RM, Krystosek A, and Sinensky M (1995). The farnesyl protein transferase inhibitor BZA-5B blocks farnesylation of nuclear lamins and p21ras but does not affect their function or localization. Cancer Res 55, 3295-3304.
54. Lebowitz PF, and Prendergast GC (1998). Non-ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogens 17, 1439-1445 (11 reviews).
55. Prendergast GC, Davide JP, DeSolms SJ, Giuliani EA, Graham SL, Gibbs JB, Oliff A, and Kohl NE (1994). Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 14, 4193-4202.
56. Lebowitz PF, Davide JP, and Prendergast GC (1995). Evidence that farnesyltransferase inhibitors suppress ras transformation by interfering with Rho activity. Mol Cell Biol 15, 6613-6622.
57. Du W, Lebowitz PF, and Prendergast GC (1999). Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 19, 1831-1840.
58. Du W, and Predergast GC (1999). Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesylated inhibitors. Cancer Res 59, 5492-5496.